Retrospective Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Feb 7, 2016; 22(5): 1859-1868
Published online Feb 7, 2016. doi: 10.3748/wjg.v22.i5.1859
Table 1 Modality-specific staging criteria
StageCriteria
T stageCT criteria
T2/3Neoplasm shows focal or diffuse thickening of gastric wall with transmural involvement, is almost well enhanced, and has smooth outer wall border and clear fat plane around tumor
T4aTransmural tumor with irregular or nodular outer border and/or perigastric fat infiltration
T4bObliteration of fat plane between gastric tumor and adjacent organ or invasion of adjacent organ
M stageCT criteria
M0Distant metastasis absent
M1Distant metastasis present
T stageEUS criteria
T2/3Tumor extent beyond the muscularis propria up to 4 mm
T4aTumor extent beyond the muscularis propria greater than 4 mm
T4bDirect extension and invasion of tumor into adjacent organ
M stageEUS criteria
M0Distant metastasis absent
M1Distant metastasis present
T stageSL criteria
T2/3Tumor with clear and smooth outer gastric surface
T4aTumor with nodular or irregular outer gastric surface
T4binfiltration of adjacent organs
M stageSL criteria
M0Distant metastasis absent
M1Distant metastasis present
Table 2 Agreement of computed tomographic and laparoscopic staging of T stage (n = 582)
Computed tomography
Staging laparoscopy
T2/3T4aT4bT2/3T4aT4b
Final stage
T2/3115353126270
T4a821764492121
T4b22136900167
Acc.Sens.Spec.PPVNPVAcc.Sens.Spec.PPVNPV
T2/376%75%76%53%90%87%82%89%72%93%
T4a56%67%47%51%63%87%81%92%89%85%
T4b72%5%98%56%72%100%100%100%99%100%
Table 3 Agreement of endoscopic and laparoscopic staging of T stage (n = 150)
Endoscopic ultrasound
Staging laparoscopy
T2/3T4aT4bT2/3T4aT4b
Final stage
T2/3284236490
T4a429188421
T4b011150026
Acc.Sens.Spec.PPVNPVAcc.Sens.Spec.PPVNPV
T2/367%38%95%88%62%89%88%90%89%88%
T4a50%57%46%35%68%88%82%91%82%91%
T4b79%58%83%42%90%99%100%99%96%100%
Table 4 Agreement of computed tomographic and laparoscopic staging of M stage (n = 582)
Computed tomography
Staging laparoscopy
M0M1M0M1
Final stageM044224440
M1121172136
Acc.Sens.Spec.PPVNPVAcc.Sens.Spec.PPVNPV
M179%89%79%12%100%100%100%100%99%100%
Table 5 Relationship between clinicopathologic features determined by clinical staging and peritoneal metastasis or positive cytology (n = 582)
CharacteristicP-negative(n = 457)P-positive(n = 125)P value
Gender0.001
Male (n = 397)32869
Female (n = 185)12956
Age0.573
< 65 (n = 441)33488
≥ 65 (n = 141)12337
ECOG score0.751
0 (n = 224)17549
1 (n = 291)22764
2 (n = 67)5512
Tumor size (mm)< 0.001
< 40 (n = 238)21521
≥ 40 (n = 346)242104
Upper third0.903
Not involved (n = 455)35897
Involved (n = 127)9928
Middle third< 0.001
Not involved (n = 401)33368
Involved (n = 181)12457
Lower third0.750
Not involved (n = 200)15941
Involved (n = 382)29884
fT stage< 0.001
T2/3 (n = 153)1458
T4a (n = 262)23230
T4b (n = 167)8087
Borrmann type< 0.001
Type I or II (n = 285)26520
Type III (n = 253)16687
Type IV (n = 44)2618
Differentiation0.293
Differentiated (n = 577)454123
Undifferentiated (n = 5)32
Lymph node metastasis0.305
Negative (n = 240)18357
Positive (n = 342)27468
Table 6 Correlation between clinicopathologic features determined by clinical staging and peritoneal metastasis or positive cytology (multivariate analysis)
VariablesP valueOdd ratio95%CI
Tumor size (mm)
< 401.000
≥ 400.0152.1231.160-3.887
fT stage< 0.001
T2/31.000
T4a0.2151.7140.731-4.020
T4b< 0.00111.544.942-26.947
Borrmann type< 0.001
Type I or II1.000
Type III< 0.0016.2913.524-11.231
Type IV< 0.0015.8442.457-13.904
Table 7 Indications for staging laparoscopy determined based on the number of independent risk factors
No. of independentrisk factorsP0 CY0P1 or CY1Total
0, 131419333
2, 3143106249
Total457125582
Accuracy72%
Sensitivity85%
Specificity69%
PPV43%
NPV94%